Opus Genetics (IRD) Return on Capital Employed (2018 - 2026)

Opus Genetics (IRD) has 9 years of Return on Capital Employed data on file, last reported at 87.51% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 26453.0% year-over-year to 87.51% in Q1 2026; TTM through Mar 2026 was 87.51%, a 26453.0% increase from a year earlier, with the FY2025 full-year figure at 107.9%, up 7408.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 87.51%, up from 109.03% in the prior quarter.
• Over the last five years, Return on Capital Employed for IRD reached as high as 64.73% in Q3 2023 and fell as low as 784.63% in Q3 2025.
• Historically, Return on Capital Employed has averaged 129.66% across 5 years, with a median of 87.51% in 2026.
• Across the five-year window, Return on Capital Employed slumped 70393 bps in 2025 and surged 26453 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 62.79% in 2022, then sank by 134 bps to 21.11% in 2023, then plunged by 976 bps to 227.12% in 2024, then soared by 52 bps to 109.03% in 2025, then rose by 20 bps to 87.51% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 87.51% in Q1 2026, 109.03% in Q4 2025, and 784.63% in Q3 2025.